𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of daunorubicin in previously untreated patients with advanced colorectal carcinoma

✍ Scribed by Harvey, J. ;Bonnem, E. ;Grady, K. ;Goodman, A. ;Schein, P.

Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
111 KB
Volume
13
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Fourteen patients with advanced measurable colorectal cancer were treated with daunorubicin hydrochloride (DNR). The drug was administered at a dose of 15 mg/m2 on day 1 through 3 and 8 through 10. After a Cday rest period DNR was given in weekly injections of 15 mg/m2. There were no partial or complete responses. This study failed to confirm the previously reported therapeutic activity of this agent in colorectal carcinoma, using an identical dose and schedule. We have initiated a phase I study of daunorubicin to identify a maximum tolerated dose using an every 3week schedule for future phase II trials in solid tumors.

πŸ“œ SIMILAR VOLUMES

Capecitabine in combination with docetax
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma
✍ Marco Venturini; Antonio Durando; Ornella Garrone; Maria Antonietta Colozza; Ant πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the activity and safety of oral capecitabine in combination with docetaxel and epirubicin (TEX) as first‐line treatment for patients with locally advanced/metastatic breast carcinoma. ## METHODS This open‐label, Phase II study